Frequency of Cardiac Valvulopathies in Patients With Marfan Syndrome: A Systematic Review and Meta-Analysis

Carlson Sama; Noah T. Fongwen; Muchi Ditah Chobufo; Ademola Ajibade; Melissa Roberts; Mark Greathouse; Anthony Lyonga Ngonge; Ayowumi Adekolu; Yasmin S. Hamirani

doi:10.7759/cureus.54141

Back

Frequency of Cardiac Valvulopathies in Patients With Marfan Syndrome: A Systematic Review and Meta-Analysis

Journal article

Open access

Peer reviewed

Frequency of Cardiac Valvulopathies in Patients With Marfan Syndrome: A Systematic Review and Meta-Analysis

Carlson Sama, Noah T. Fongwen, Muchi Ditah Chobufo, Ademola Ajibade, Melissa Roberts, Mark Greathouse, Anthony Lyonga Ngonge, Ayowumi Adekolu and Yasmin S. Hamirani

Curēus (Palo Alto, CA), Vol.16(2), e45141

02/13/2024

DOI: 10.7759/cureus.54141

PMCID: PMC10940034

PMID: 38487153

Files and links (1)

url

https://doi.org/10.7759/cureus.54141View

Published (Version of record) Open Access

Abstract

Marfan syndrome (MFS) is a progressive connective tissue disease with a broad range of clinical manifestations. We sought to establish the spectrum of structural valvular abnormalities as cardiovascular involvement has been identified as the most life-threatening aspect of the syndrome. This was a systematic review with a meta-analysis of studies indexed in Medline from the inception of the database to November 7, 2022. Using the random-effects model, separate Forest and Galbraith plots were generated for each valvular abnormality assessed. Heterogeneity was assessed using the I2 statistics whilst funnel plots and Egger's test were used to assess for publication bias. From a total of 35 studies, a random-effects metaanalysis approximated the pooled summary estimates for the prevalence of cardiac valve abnormalities as mitral valve prolapse 65% (95% CI: 57%-73%); mitral valve regurgitation 40% (95% CI: 29%-51%); aortic valve regurgitation 40% (95% CI: 28%-53%); tricuspid valve prolapse 35% (95% CI: 15%-55%); and tricuspid valve regurgitation 43% (95% CI: 8%-78%). Only one study reported on the involvement of the pulmonary valve (pulmonary valve prolapse was estimated at 5.3% (95% CI: 1.9%-11.1%) in a cohort of 114 patients with MFS). We believe this study provides a description of the structural valvular disease spectrum and may help inform providers and patients in understanding the clinical history of MFS in the current treatment era with its increased life expectancy.

General & Internal Medicine

Life Sciences & Biomedicine

Medicine, General & Internal

Science & Technology

Details

Title: Subtitle: Frequency of Cardiac Valvulopathies in Patients With Marfan Syndrome: A Systematic Review and Meta-Analysis
Creators: Carlson Sama - West Virginia University
Noah T. Fongwen - Africa Centres for Disease Control and Prevention
Muchi Ditah Chobufo - West Virginia University
Ademola Ajibade - West Virginia University
Melissa Roberts - West Virginia University
Mark Greathouse - West Virginia University
Anthony Lyonga Ngonge - Morehouse School of Medicine
Ayowumi Adekolu - West Virginia University
Yasmin S. Hamirani - West Virginia University
Resource Type: Journal article
Publication Details: Curēus (Palo Alto, CA), Vol.16(2), e45141
DOI: 10.7759/cureus.54141
PMID: 38487153
PMCID: PMC10940034
NLM abbreviation: Cureus
ISSN: 2168-8184
eISSN: 2168-8184
Publisher: Springer Nature
Number of pages: 15
Language: English
Date published: 02/13/2024
Academic Unit: Internal Medicine
Record Identifier: 9984845466002771

Metrics

30 Record Views